Neuphoria Therapeutics Inc.
NEUP
$4.12
-$0.25-5.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.65M | 15.65M | 15.66M | 662.70K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.65M | 15.65M | 15.66M | 662.70K | -- |
| Cost of Revenue | -1.90M | -1.90M | -2.97M | -3.39M | -3.09M |
| Gross Profit | 17.55M | 17.55M | 18.63M | 4.05M | 3.09M |
| SG&A Expenses | 7.97M | 7.77M | 8.08M | 7.87M | 7.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.56M | 16.48M | 16.13M | 15.50M | 15.90M |
| Operating Income | -2.91M | -829.10K | -470.60K | -14.84M | -15.90M |
| Income Before Tax | -9.84M | -838.00K | 5.59M | -8.35M | -11.01M |
| Income Tax Expenses | -371.00K | -468.40K | -235.90K | -138.30K | -184.70K |
| Earnings from Continuing Operations | -9.47 | -0.37 | 5.83 | -8.21 | -10.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.47M | -369.60K | 5.83M | -8.21M | -10.82M |
| EBIT | -2.91M | -829.10K | -470.60K | -14.84M | -15.90M |
| EBITDA | -2.25M | -166.30K | 192.20K | -14.17M | -15.23M |
| EPS Basic | -3.77 | 0.03 | 1.34 | -8.04 | -12.12 |
| Normalized Basic EPS | -2.55 | -0.24 | -1.00 | -6.82 | -9.40 |
| EPS Diluted | -3.77 | 0.02 | 1.34 | -8.04 | -12.12 |
| Normalized Diluted EPS | -2.55 | -0.24 | -1.00 | -6.82 | -9.40 |
| Average Basic Shares Outstanding | 7.44M | 6.49M | 5.39M | 4.66M | 3.94M |
| Average Diluted Shares Outstanding | 7.44M | 6.49M | 5.39M | 4.66M | 3.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |